Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 851 - 875 of 14771 in total
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Milk thistle is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Investigational
Matched Categories: … Herbs and Natural Products …
A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Approved
Matched Description: … A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment …
Matched Categories: … Alimentary Tract and Metabolism ... propantheline and psycholeptics …
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it...
Approved
Investigational
Matched Description: … As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and ... inhibiting protein and DNA synthesis. ... [A1407] Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
Approved
Matched Description: … It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. ... Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B …
Matched Categories: … Blood and Blood Forming Organs ... Vitamin B12 and Folic Acid …
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and ... amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and ... a comparatively favorable adverse effect profile as compared to other available treatment options, and
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture …
Matched Categories: … meropenem and vaborbactam …
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … typically associated with a poorer prognosis (as compared to "classical" _EGFR_ mutants causing NSCLC) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically,...
Approved
Investigational
Matched Description: … Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most ... generally more effective and tolerable than its predecessor. ... synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and
Matched Categories: … Decongestants and Antiallergics …
A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is...
Approved
Matched Description: … of myasthenia and as a fluorescent probe in HPLC. ... (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment …
Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and ... It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011 …
Matched Categories: … indacaterol and mometasone ... indacaterol and glycopyrronium bromide ... indacaterol, glycopyrronium bromide and mometasone …
Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …
Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Polistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. Cresols are precursors or synthetic intermediates to various other compounds and materials, including plastics, pesticides, pharmaceuticals, disinfectants, and dyes. Ingestion of cresol induces toxicity...
Approved
Matched Description: … pain, and/or vomiting. ... Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal ... Pure cresol is a mixture of ortho-, meta-, and para- isomers. …
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011....
Approved
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Description: … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. ... is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and ... This drug was approved after being designed as an orphan drug with a fast track and priority review status …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Karaya gum allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Equipment and Supplies ... Alimentary Tract and Metabolism …
Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon. Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as DB14184 within commercial products. Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% . Sensitivity...
Approved
Experimental
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. ... Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development ... first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Description: … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved ... By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and ... in cytokine signalling and hematopoiesis. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 851 - 875 of 14771 in total